Quantum convoy covers 1,000 miles for cancer

Pharmaceutical specials manufacturer raises £5,000 for charity

Ten amateur cyclists from pharmaceutical manufacturer Quantum Pharmaceutical have completed a 1,000-mile charity bike ride to raise £5,000 for Marie Curie Cancer Care.

The team signed up for the challenge after their colleague Tony Gallagher died of cancer in 2008.

Gallagher’s son, Scott, led the cycle convoy, which rode off from Land’s End in Cornwall and cycled up to 90 miles a day to cross the finishing line at John O’Groats in Caithness, Scotland a fortnight later.

‘It was a testing couple of weeks,’ said Quantum Pharmaceutical’s managing director Andy Scaife.

‘We remember Tony so fondly, and cycling a thousand miles will be nothing compared with the challenge he faced in fighting cancer. We just hope the money we raise will help other cancer sufferers as they battle with the disease.’

Quantum Pharmaceutical, based in Burnopfield, Co Durham, UK, is a pharmaceutical specials manufacturer licensed by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to supply pharmacies, chemists, dispensing doctors and hospitals with bespoke medicines.

You may also like

Regulatory

Penn Pharma recalls batches of seizure drug

Following incorrect placement of screw caps on some units of Midazolam buccal liquid, which could affect drug concentration
Containment

Quantum Pharmaceutical opens aseptic manufacturing facility

Incorporates aseptic compounding and manufacturing services, including gassing isolators
Manufacturing

Quantum Pharmaceutical moves into new HQ

Opens up potential for further expansion of the UK specials manufacturer
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Subscribe now